Dovitinib in combination with fulvestrant showed promising clinical activity in a FGF pathway-amplified subgroup. However, the data reported from this study should be interpreted with caution, given that fewer progression-free survival events occurred in the FGF pathway-amplified patients than was expected.
Breast Cancer Res